UT Southwestern Medical Center researchers have found that intermittent fasting inhibits the development and progression of the most common type of childhood leukemia.
This Saturday [Dec 3], the 58th Annual Meeting of the American Society of Hematology will begin in San Diego, where the latest advances in research for blood cancers including leukemia, lymphoma, and myeloma will be highlighted during the four days of talks and poster presentations.
Members of the TET family of proteins help protect against cancer by regulating the chemical state of DNA —and thus turning growth-promoting genes on or off. The latest findings reported by researchers at La Jolla Institute for Allergy and Immunology illustrate just how important TET proteins are in controlling cell proliferation and cell fate.
In the first study evaluating patient-reported cosmetic outcomes in a population-based cohort of older women with breast cancer, The University of Texas MD Anderson Cancer Center researchers found that less radiation was associated with improved cosmetic satisfaction long-term.
In a pilot study conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy and/or targeted therapy, neoadjuvant systemic therapy (NST).
Leaders from Fred Hutch, Seattle Cancer Care Alliance and Juno Therapeutics will speak on immunotherapy's roots in Seattle, new clinical trials and the prospects for developing new cures for cancer during a Dec. 12 scientific symposium to celebrate the opening of the first-of-its-kind clinic
A genomic analysis study by Rutgers Cancer Institute of New Jersey investigators and other colleagues has identified recurrent genomic alterations in a subset of breast cancer that are typically associated with a form of thyroid cancer and an intestinal birth defect known as Hirschsprung disease.
A study presented Wednesday at the 2016 San Antonio Breast Cancer Symposium examined the incidence of brain metastasis after diagnosis for three groups of patients with HER2-positive breast cancer.
AACI applauds the Senate for passing the 21st Century Cures Act. The innovative legislation will provide nearly $4.8 billion in funding for the National Institutes of Health (NIH) over the next ten years via a NIH Innovation Account.
The Ludwig Institute for Cancer Research extends a warm welcome to Barbara S. Jones, the newest member of our Board of Directors.
Two nonprofits team up to fund immunotherapy research designed to benefit patients with an ultra-rare form of liver cancer.
A Yale Cancer Center team has evaluated the use of hypomethylating agents in patients suffering from Acute Myeloid Leukemia (AML) who were resistant to treatment with intensive chemotherapy.
Fred Hutchinson Cancer Research Center announced promising results from an early trial in which patients with high-risk acute myeloid leukemia received genetically engineered immune cells. Of the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.
Doctors at Yale believe immunotherapy is causing a new type of acute-onset diabetes, with at least 17 cases so far.
The immunotherapy drug nivolumab in combination with standard chemotherapy more than doubled response rates and improved overall survival in patients with acute myeloid leukemia (AML), according to preliminary findings by researchers at The University of Texas MD Anderson Cancer Center.
In a recent study, a Yale Cancer Center team confirmed expectations of higher healthcare utilization and costs with relapsed Diffuse Large B-Cell Lymphoma (DLBCL).
Richard Gorlick, M.D., an internationally recognized expert in pediatric oncology and hematology, today joined The University of Texas MD Anderson Children’s Cancer Hospital as the division head and department chair of Pediatrics.
TAMPA, Fla. – Immune cellular therapy is a promising new area of cancer treatment. Anti-cancer therapeutics, such as chimeric antigen receptor (CAR) modified T cells, can be engineered to target tumor-associated antigens to attack and kill cancer cells. This allows for an improved precision medicine approach to treating cancer.
Patients who potentially could benefit most from participation in clinical trials due to poor prognoses often are not included based on eligibility criteria, such as existing medical illnesses.
In a small, early phase trial, a high percentage of patients who had exhausted most traditional treatments for chronic lymphocytic leukemia saw their tumors shrink or even disappear after an infusion of a highly targeted, experimental CAR T-cell immunotherapy developed at Seattle’s Fred Hutchinson Cancer Research Center.
Patients successfully treated for breast, colon and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after completion of treatment, due to a genetic mutation leading to secondary malignancies known as therapy-related myeloid neoplasms (t-MNs).
Analysis of a phase 3 trial shows that older patients with high-risk or secondary AML, who received initial treatment with CPX-351, had improved survival following allogeneic hematopoietic cell transplant, when compared with patients who received standard 7+3 cytarabine and daunorubicin as initial therapy.
Patients with myelodysplastic syndromes (MDS) suffer from a reduction in the number of different types of blood cells, including red blood cells leading to the development of anemia. Many patients with lower-risk MDS benefit from treatment with recombinant-erythropoietin (rHuEPO), which stimulates blood cell production.
The American Cancer Society (ACS), the largest non-government, not-for-profit funding source of cancer research in the United States, has approved funding for three new research grants totaling over $1.7 million to investigators at Yale University.
A new drug has been approved by the FDA in the fight against lung cancer. Tecentriq is being used by patients like Cornelius Bresnan, who had late-stage cancer.
Researchers led by scientists at Dana-Farber Cancer Institute say they have identified unique genomic changes that may be integral to testicular cancer development and explain why the great majority are highly curable with chemotherapy – unlike most solid tumors.
New collaboration between two nonprofits focused on cancer immunotherapy aims to identify new DNA-based targets for personalized cancer treatments
In a small double-blind study, Johns Hopkins researchers report that a substantial majority of people suffering cancer-related anxiety or depression found considerable relief for up to six months from a single large dose of psilocybin -- the active compound in hallucinogenic "magic mushrooms."
The U.S. House of Representatives on Wednesday passed a revised version of the 21st Century Cures Act. The bill including $1.8 billion for cancer research.
An international group of researchers report success in mice of a method of using positron emission tomography (PET) scans to track, in real time, an antibody targeting a hormone receptor pathway specifically involved in prostate cancer.
NCCN will host its annual patient advocacy summit on December 9 in Washington, DC to explore gaps in current value tools, as well as patient definitions of value.
For the first time, researchers have found higher levels of Gram-negative bacteria antigens in brain samples from late-onset Alzheimer’s disease patients. Compared to controls, patients with Alzheimer's had much higher levels of lipopolysaccharide (LPS) and E coli K99 pili protein. In addition, The UC Davis team also found LPS molecules congregated with amyloid plaques, which have been linked to Alzheimer’s pathology and progression. The research was published today in the print edition of the journal Neurology.
A new clinical study underway at Roswell Park Cancer Institute is the first to test the combination of the immunotherapy pembrolizumab with two other drugs as treatment for recurrent epithelial ovarian cancer, and is also the first ovarian cancer clinical trial to incorporate analysis of patients’ microbiomes
Nearly 20 years have passed since Memorial Sloan Kettering Cancer Center (MSK) first opened its doors in the Garden State. Since then, an explosion of knowledge and data has resulted in far better outcomes for thousands of people with cancer, including many who’ve sought care at MSK’s facility in New Jersey.
A cellular component known as the Golgi apparatus may play a role in how lung cancer metastasizes, according to researchers at The University of Texas MD Anderson Cancer Center whose findings were reported in the Nov. 21 online issue of the Journal of Clinical Investigation.
NCCN Imaging AUC™ provide a single access point for all oncology imaging recommendations within the NCCN Guidelines®; currently, NCCN Imaging AUC™ are available for 35 NCCN Guidelines.
NCCN has published NCCN Guidelines for Patients®: Nausea and Vomiting, available on NCCN’s new mobile app for patients.
As reported in JNCCN, a recent study from McGill University shows that while opioid use increases during treatment in older patients with breast cancer, most do not continue use into survivorship; however, use of anxiolytics and antidepressants remains high in survivors.
In recognition of wide-ranging contributions to the fields of cancer prevention, patient care, and basic, translational, and clinical research, seven faculty members from The University of Texas MD Anderson Cancer Center have been named Fellows of the American Association for the Advancement of Science (AAAS).
Lung-MAP (SWOG S1400) is a multi-drug, multi-sub-study, biomarker-driven squamous cell lung cancer clinical trial that uses state-of-the-art genomic profiling to match patients to sub-studies testing investigational treatments that may target the genomic alterations, or mutations, found to be driving the growth of their cancer.
Professor Roy S. Herbst, M.D., Ph.D., Yale University, New Haven, will be recognized by The International Association for the Study of Lung Cancer with a Distinguished Award at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.
Cancer is the leading cause of death in San Francisco and costs patients, families and taxpayers hundreds of millions of dollars each year. Seeing an opportunity to change this, a group that includes UC San Francisco (UCSF), the City and County of San Francisco, the San Francisco Department of Public Health (DPH), and health care and community organizations has launched the San Francisco Cancer Initiative (SF CAN), a major public health effort to reduce cancer in San Francisco.
Immunotherapy continues to revolutionize the field of non–small cell lung cancer (NSCLC), with researchers now focusing on the optimal use of immune agents in the frontline setting.
New data presented at a cancer conference suggests that more than three in five Australian breast cancer survivors are overweight or obese – and that it’s likely to increase their risk of cancer returning.
Researchers leading the largest genomic tumor profiling effort of its kind say such studies are technically feasible in a broad population of adult and pediatric patients with many different types of cancer.
Glioblastoma multiforme remains the most common and highly lethal brain cancer and is known for its ability to relapse.
Researchers are studying a new injectable chemo that has shown to be successful in canines.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right